|Oncology||Pre-Clinical||Lead||President & CEO|
GLyPharma is a new company created in Montreal for the purpose of a strategic partnership between Ferring Pharmaceuticals (Ferring) ,a European pharmaceutical company,FONDS de solidarité FTQ and CTI Life Sciences Fund aimed at developing a Ferring asset by importing it to the province of Quebec. The compound is a long-acting GLP-2 receptor agonist, currently at pre-IND stage. It will be tested for a first-in-class indication in supportive care in oncology. GlyPharma is granted by Ferring an exclusive worldwide license for development and commercialization of the compound in oncology.
GLyPharma Therapeutic Inc.
1 Place Ville-Marie, Suite 2001
Montreal, QC, Canada
Telephone: (514) 876-4220
Fax: (514) 866-2115